BiPER Therapeutics develops first-in-class selective BiP inhibitors as targeted therapy with a first focus on treating cancer patients
BiPER Therapeutics develops first-in-class selective BiP inhibitors as targeted therapy with a first focus on treating cancer patients. Their approach induces unresolved ER stress in cancer cells to promote cell death while strengthening non-cancer cells.